Unknown

Dataset Information

0

Immunomodulatory Drugs in Melanoma Brain Metastases.


ABSTRACT: Brain metastases are about ten times more frequent than a brain primary tumor, being present in 20-40% of adults with systemic cancer. Together with lung cancer and breast cancer, skin cancers such as melanoma are top primary tumors which metastasizes to the brain. Advanced melanoma is well known for its propensity to metastasize to the brain, with 80% of patients presenting brain metastasis at the autopsy. However, current therapies are not very efficient and brain metastases are in most of the cases lethal. Treatment of melanoma brain metastases with surgery and/or radiation therapy results in a median overall survival of only about four months after diagnosis. New immunotherapies such as targeted or immunomodulatory drugs, many in clinical trials, have shown promise, with some immunomodulatory drugs being able to at least double the overall survival rates for patients with melanoma brain metastases. This review focuses on the recent advances and future potential of using immunotherapy, such as the newly developed immunomodulatory drugs, for melanoma brain metastases therapy. Immunomodulatory drugs bring a great promise as new tools for melanoma treatment in particular and for the treatment of other types of malignancies in general.

SUBMITTER: Fernandes GNC 

PROVIDER: S-EPMC7086063 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immunomodulatory Drugs in Melanoma Brain Metastases.

Fernandes Gil Nuno Castro GNC  

Discoveries (Craiova, Romania) 20190626 2


Brain metastases are about ten times more frequent than a brain primary tumor, being present in 20-40% of adults with systemic cancer. Together with lung cancer and breast cancer, skin cancers such as melanoma are top primary tumors which metastasizes to the brain. Advanced melanoma is well known for its propensity to metastasize to the brain, with 80% of patients presenting brain metastasis at the autopsy. However, current therapies are not very efficient and brain metastases are in most of the  ...[more]

Similar Datasets

| S-ECPF-GEOD-50496 | biostudies-other
| S-EPMC6094653 | biostudies-literature
2014-05-08 | E-GEOD-50496 | biostudies-arrayexpress
| S-EPMC5378732 | biostudies-literature
2014-05-08 | GSE50496 | GEO
| S-EPMC7860978 | biostudies-literature
| S-EPMC7443369 | biostudies-literature
| EGAS00001002107 | EGA
| S-EPMC4955922 | biostudies-literature
| S-ECPF-GEOD-50493 | biostudies-other